A Single-Dose, Randomized, Open-Label, Crossover, Comparative Bioavailability Study of TRIA-662 500 mg Immediate-Release Tablets and NIASPAN 1000 mg Extended-Release Tablets in Healthy Male and Female Volunteers Under Fed Conditions
Latest Information Update: 24 Aug 2013
At a glance
- Drugs N-1-methylnicotinamide (Primary) ; Niacin
- Indications Lipid metabolism disorders
- Focus Pharmacokinetics
- 01 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Mar 2013 New trial record